Cancer Liquid Biopsy Market Assessment

 
Online Download $2,500
Departmental Site License (one location, 10 users) $3,750
Global Site License $5,000
Published Nov 8, 2017 | 91 Pages | Pub ID: KLI15527193

Cancer Liquid Biopsy Market Assessment (Breast Cancer, Colorectal Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer)

The term liquid biopsy encompasses various diagnostic methods that use liquid, non-tissue specimens to provide information that can aid in the diagnosis, treatment and monitoring of cancer. Currently, tissue biopsies, along with imaging techniques, are the standard methods used in the diagnosis of solid cancers, but despite their widespread use, they have many limitations that open the door for other diagnostic technologies in oncology clinical settings.

The Worldwide Market for Liquid Biopsy contains markets for the following:

Breast Cancer Liquid Biopsy Market (by Region - US, EUR, ASIA, ROW)

Colorectal Cancer Liquid Biopsy Market (by Region - US, EUR, ASIA, ROW)

Lung Cancer Liquid Biopsy Market (by Region - US, EUR, ASIA, ROW)

Ovarian Cancer Liquid Biopsy Market (by Region - US, EUR, ASIA, ROW)

Pancreatic Cancer Liquid Biopsy Market (by Region - US, EUR, ASIA, ROW)

Other Cancer Liquid Biopsy Market (by Region - US, EUR, ASIA, ROW)

Top Ten Companies in the Market

The currently available liquid biopsy technologies employ the analysis of various types of analytes, including circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), extracellular vesicles, proteins, miRNA and mRNA. Among them, ctDNA and CTCs have been the most explored technologies for commercial applications up to the present time.

Circulating tumor DNA (ctDNA) encompasses the small fragments of DNA that are believed to originate from the natural and abnormal necrosis and apoptosis processes that tumor cells undergo regularly. ctDNA fragments have the advantage of being available from different types of specimens, including urine, plasma, blood, and cerebrospinal fluid, but are rare and have a short half-life in the bloodstream, which makes their isolation and identification highly challenging. Since many cancer patients shed only very small DNA fragments into the bloodstream, ctDNA-based diagnostic technologies need to be highly sensitive in order to detect such rare events. Furthermore, ctDNA cannot provide information about protein expression, and the analysis of RNA is also difficult and limited using ctDNA. ctDNA may also result from tumor cells killed by therapeutic drugs, and does not capture information about the residual cancer that may not respond to the particular therapy or has become resistant to it.

Circulating tumor cells (CTCs) are cancer cells that are believed to detach from primary or secondary tumors and enter the bloodstream, traveling to distant organs, initiating the process of metastasis, and forming new tumors. Similarly to ctDNA, CTC-based tests could offer significant advantages compared to tissue biopsies, as they may be able to capture the heterogeneity of tumors and their genetic evolution during the disease progression and therapy. Compared to ctDNA, CTCs have a longer half-life in blood, and the analysis of viable cells could provide information about protein expression, such as PD-L1 or ER, which is not possible with ctDNA. Also, since CTCs contain intact genomic material from tumors, their analysis can reveal additional information about the biology of cancer and metastasis that is not possible to obtain from ctDNA.

This report segments market by type of cancer and corresponding regional market. For segmentation by type of analyte and type of application, see Kalorama's larger study on Liquid Biopsy Markets.
CHAPTER ONE: EXECUTIVE SUMMARY
INTRODUCTION
LIQUID BIOPSY TECHNOLOGIES
INDUSTRY STRUCTURE
LIQUID BIOPSY MARKET REVENUES AND FORECAST
CHAPTER TWO: LIQUID BIOPSY TECHNOLOGIES
INTRODUCTION
Table 2-1 Comparison of Tissue and Liquid Biopsy
CURRENT MAJOR LIQUID BIOPSY TECHNOLOGIES
Table 2-2 Advantages and Limitations of Major Liquid Biopsy Technologies
CIRCULATING FREE DNA
ADVANTAGES AND LIMITATIONS OF CTDNA IN LIQUID BIOPSY
CURRENT CTDNA-BASED LIQUID BIOPSY TESTS
Table 2-3 Selected Market-Available ctDNA-based Liquid Biopsy Tests, 2017
Adaptive Biotechnologies
Biodesix
Epigenomics
Foundation Medicine
Genomic Health
Guardant Health
Myriad Genetics
Pathway Genomics
Personal Genome Diagnostics
QIAGEN
Roche Diagnostics
Sysmex-Inostics
Trovagene
CIRCULATING TUMOR CELLS (CTCS) LIQUID BIOPSY
CHALLENGES IN THE DEVELOPMENT OF CTCS-BASED LIQUID BIOPSY TESTS
CTCS-BASED LIQUID BIOPSY TESTS
Table 2-4 Selected Market-Available CTCs-based Liquid Biopsy Tests, 2017
Biocept
Cynvenio Biosystems
Epic Sciences
GILUPI
Menarini-Silicon Biosystems
QIAGEN
EXTRACELLULAR VESICLES AND OTHER LIQUID BIOPSY
INTRODUCTION
LIQUID BIOPSY TESTS BASED ON EXTRACELLULAR VESICLES
Table 5-1 Selected Liquid Biopsy Tests Based on Extracellular Vesicles/Other Analytes, 2017
Biodesix
Exosome Diagnostics
Gensignia
Hologic
MDxHealth
OncoCyte
QIAGEN
Vermillion
VolitionRx
CHAPTER THREE: LIQUID BIOPSY INDUSTRY ANALYSIS
INTRODUCTION
TIERS OF COMPETITION
Table 3-1 Selected Competitors in the Liquid Biopsy Market, 2017
COMPETITIVE FACTORS
SIGNIFICANT MARKET TRENDS
Table 3-2 Significant Trends in the Liquid Biopsy Diagnostics and Monitoring Tests Market, 2017
Personalized Medicine to Spur Use of Liquid Biopsy Tests in Clinical Practice
Increasing Global Incidence of Cancer and Life Expectancy to Increase Testing Volumes
New Liquid Biopsy Product Launches to Augment Market Revenues
Decreasing Cost of Genetic Testing to Increase Utilization of Liquid Biopsy Tests
Regulatory Hurdles to Limit Market Growth
Limitations in Third-party Payer Coverage to Restrict Test Utilization and Market Growth
Insufficient Demonstrated Clinical Utility to Slow Adoption by Oncologists
Challenges in the Integration of Liquid Biopsy Tests in Clinical Practice to Limit Market Growth
CHAPTER FOUR: CANCER LIQUID BIOPSY MARKET ANALYSIS
OVERALL LIQUID MARKET SNAPSHOT
Table 4-1 Global Liquid Biopsy Market by Type of Cancer ($ millions), 2015-2021
Figure 4-1 Global Liquid Biopsy Market by Type of Cancer ($ millions), 2015-2021
TOP TEN COMPANIES IN THE LIQUID BIOPSY MARKET
Table 4-2 Top Ten Companies in the Liquid Biopsy Market
BREAST CANCER
Market Snapshot
Revenue Forecast
Table 4-3 Breast Cancer Liquid Biopsy Market - by Region (US, EUR, ASIA, ROW)
COLORECTAL CANCER
Market Snapshot
Revenue Forecast
Table 4-4: Colorectal Cancer Liquid Biopsy Market - by Region (US, EUR, ASIA, ROW)
LUNG CANCER
Market Snapshot
Revenue Forecast
Table 4-5: Lung Cancer Liquid Biopsy Market - by Region (US, EUR, ASIA, ROW)
OVARIAN CANCER
Market Snapshot
Revenue Forecast
Table 4-6: Ovarian Cancer Liquid Biopsy Market - by Region (US, EUR, ASIA, ROW)
PROSTATE CANCER
Market Snapshot
Revenue Forecast
Table 4-7: Prostate Cancer Liquid Biopsy Market - by Region (US, EUR, ASIA, ROW)
OTHER CANCERS
Market Snapshot
Revenue Forecast
Table 4-8: Other Cancer Liquid Biopsy Market

In this report, {{keyword[keywordTextProperty]}} appears {{keyword[keywordCountProperty]}} times. {{searchResults.STATRESULT.SUMMARY.KW[keywordTextProperty]}} appears {{searchResults.STATRESULT.SUMMARY.KW[keywordCountProperty]}} times.

We were unable to search inside this report.

Search for an exact word or phrase by placing the word or phrase in quotation marks ("market trend"). Search for different versions or tenses of a word by placing an asterisk at the end of the word (pharma*).

Please note that your term must be at least three characters long and numbers will be blocked by the # sign.